American Heart Journal
Volume 148, Issue 2 , Pages 263-268, August 2004

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial☆

  • Deepak L. Bhatt, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • Corresponding Author InformationReprint requests: Deepak L. Bhatt, MD, Cleveland Clinic Foundation, Department of Cardiovascular Medicine/Desk F25, 9500 Euclid Ave, Cleveland, OH 44195, USA.
    • ,
  • Eric J. Topol, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • CHARISMA Executive Committee

      Affiliations

    • See Appendix for a complete list of the CHARISMA Executive Committee.

Received 7 December 2003; accepted 29 March 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Supported by Sanofi-Synthelabo and Bristol-Myers Squibb.

PII: S0002-8703(04)00154-1

doi:10.1016/j.ahj.2004.03.028

American Heart Journal
Volume 148, Issue 2 , Pages 263-268, August 2004

Article Tools

* Image Usage & Resolution